Industry News
Biotechnology Industry News
Capsida Biotherapeutics has paused…
Capsida Biotherapeutics has paused a gene therapy clinical trial after the first patient died. The biotech, which began the phase 1/2 study in July, took the action to give it time to determine the root
LB Pharmaceuticals’ decision to…
LB Pharmaceuticals’ decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing this morning.
Less than two years after breaking…
Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&D center and future U.K. headquarters in London, Merck is not only bailing on the project but is discontinuing
One week after warning that the…
One week after warning that the United Kingdom is undervaluing life sciences manufacturing investments, trade organization the Association of the British Pharmaceutical Industry has issued another call to action for policymakers and the local biopharma
From now on, MEI…
From now on, MEI Pharma—previously best known for its clinical-stage leukemia drug—will be called Lite Strategy.
PMV Pharmaceuticals has reported a…
PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of
The Trump administration is…
The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times.
Robert Abel of Schrödinger…
Robert Abel of Schrödinger discusses how AI and physics-based modeling are reshaping drug discovery.
Odyssey Therapeutics’ team of…
Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D round after abandoning plans to go public this summer.
Protara applies modern science,…
Protara applies modern science, manufacturing, and regulatory expertise to reimagine proven medicines and deliver new treatment options for patients.
Capricor Therapeutics has publicly…
Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of complete response letters (CRLs) released
Pfizer veteran Suneet Varma has…
Pfizer veteran Suneet Varma has found his next role. Months after leaving the Big Pharma, Varma has taken the CEO position at the newly created inflammation and immunology startup Intent Biologics.
Eli Lilly is inviting early-stage…
Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform.
Novartis is paying $1.4 billion to…
Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its former Pfizer cardiovascular drug that impressed in a phase 2 study earlier this year.
The CNS-focused company is looking…
The CNS-focused company is looking to pull off the first biotech IPO since February and collect $228.5 million in much-needed funding for further clinical development of its schizophrenia candidate.
After previously delaying its…
After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for an ultra-rare pediatric mitochondrial disease.
Regeneron’s allergen-blocking…
Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies.
Dianthus Therapeutics is advancing…
Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase study.
Atom Therapeutics is touting data…
Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition.
A phase 2a trial of Rapport…
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading.